Navigation Links
Prion disease treatable if caught early

Studies in mice have indicated that the effects of prion disease could be reversed if caught early enough. The researchers said that their findings support developing early treatments that aim to reduce levels of prion protein in the brains of people with prion disease. Also, they said that their findings suggest testing the efficacy of treatments in a new way: by analyzing their cognitive effects in prion-infected mice.

The researchers, Giovanna Mallucci and colleagues, reported their findings in the February 1, 2007 issue of the journal Neuron, published by Cell Press.

Prion disease—such as the version of Creutzfeldt-Jakob disease believed to be contracted from cattle with "mad cow disease"—is caused by aberrant, infective proteins. It has been thought that the disease is untreatable.

However, in previous studies with prion-infected mice, Mallucci and colleagues found that early brain degeneration can be reversed if prions are depleted in neurons.

In the new studies published in Neuron, they established that cognitive and behavioral impairments—which appear early in humans with prion disease—can be reversed if prion depletion is done early. What’s more, they found that the neurological pathology of the disease is reversed along with the cognitive and behavioral deficits.

In their studies, the researchers measured the effects of prion disease on the animals?ability to discriminate novel objects in their cage and on normal burrowing behavior. In both cases, deficits in those abilities appeared early in the disease. Also, studies of the animals?brain tissue revealed a parallel impairment of signaling among brain cells.

However, when the researchers manipulated the animals to deplete their brains of the prion protein, their memory ability and burrowing behavior recovered. Importantly, found the researchers, the signaling among brain cells also recovered.

"Overall, we conclude that the dramatic benefits to neuronal function and survival in prion-infected mice we have shown here support targeting neuronal [prion protein] directly as a therapeutic approach," wrote Mallucci and colleagues.

"Our findings of early reversible neurophysiological and cognitive deficits occurring prior to neuronal loss open new avenues in the prion field," they wrote. "To date, prion infection in mice has conventionally been diagnosed when motor deficits reflect advanced neurodegeneration. Now the identification of earlier dysfunction helps direct the study of mechanisms of neurotoxicity and therapies to earlier stages of disease, when rescue is still possible.

"Eventually it may also enable preclinical testing of therapeutic strategies through cognitive endpoints. These data now lead to the hope that early intervention in human prion disease will not only halt clinical progression but allow reversal of early behavioral and cognitive abnormalities," wrote the scientists.

Source:Cell Press

Related biology news :

1. Fibril Shape Is The Basis Of Prion Strains And Cross-species Prion Infection
2. Active Vaccine Prevents Mice From Developing Prion Disease
3. Prions rapidly remodel good protein into bad, Brown study shows
4. Prion find points way to test for human mad cow disease
5. Neuronal traffic jam marks early Alzheimers disease
6. Scientists detect probable genetic cause of some Parkinsons disease cases
7. Ecological destruction fuels emerging diseases
8. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
9. U of M researcher examines newly emerging deadly disease
10. Marburg virus disease in Angola - update
11. Molecular machine may lead to new drugs to combat human diseases

Post Your Comments:

(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
Breaking Biology Technology: